Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C

Value in Health

Volumn 19, Issue 5, 2016, Pages 544-551

  Younossi, Zobair M ^a,b   Stepanova, Maria ^c   Henry, Linda ^b,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

Author keywords

hepatitis C; HRQOL; measurement tool; patient reported outcomes; quality of life

Indexed keywords

ANEMIA; ARTICLE; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE QUESTIONNAIRE HEPATITIS C VERSION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CRONBACH ALPHA COEFFICIENT; DEMOGRAPHY; HUMAN; INTERNAL CONSISTENCY; LIKERT SCALE; LIVER CIRRHOSIS; MEDICAL HISTORY; MENTAL DISEASE; PATHOGEN CLEARANCE; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; SHORT FORM 36; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY; VALIDATION STUDY; VALIDITY; ADOLESCENT; ADULT; FEMALE; HEPACIVIRUS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STANDARDS; YOUNG ADULT;

ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84964662715     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.02.005     Document Type: Article

References (54)

1. [1] Rodger, A.J., Roberts, S., Lanigan, A., et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971–1975. Hepatology 32 (2000), 582–587.
2. [2] Zarski, J.P., McHutchison, J., Bronowicki, J.P., et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 38 (2003), 307–314.
3. [3] Hajarizadeh, B., Grebely, J., Dore, G.J., Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10 (2013), 553–562.
4. [4] Leone, N., Rizzetto, M., Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 51 (2005), 31–46.
5. [5] Younossi, Z.M., Kanwal, F., Saab, S., et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39 (2014), 518–531.
6. [6] El-Serag, H.B., Hampel, H., Yeh, C., Rabeneck, L., Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36 (2002), 1439–1445.
7. [7] Louie, K.L., Forssen, U.M., Mundy, L.M., Pimenta, J.M., The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis, 12, 2012, 86.
8. [8] John-Baptiste, A.A., Tomlinson, G., Hsu, P.C., et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 104 (2009), 2439–2448.
9. [9] Bronowicki, J.P., Ouzan, D., Asselah, T., et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131 (2006), 1040–1048.
10. [10] Häuser, W., Holtmann, G., Grandt, D., Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2 (2004), 157–163.
11. [11] Laouénan, C., Guedj, J., Peytavin, G., et al. A model-based illustrative exploratory approach to optimize the dosing of peg-IFN/RBV in cirrhotic hepatitis C patients treated with triple therapy. CPT Pharmacometrics Syst Pharmacol, 4, 2015, e00008.
12. [12] Matsushita, H., Ikeda, F., Iwasaki, Y., et al. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 29 (2014), 337–343.
13. [13] Hollander, A., Foster, G.R., Weiland, O., Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 41 (2006), 577–585.
14. [14] Dan, A.A., Martin, L.M., Crone, C., et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 44 (2006), 491–498.
15. [15] Dan, A.A., Crone, C., Wise, T.N., et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics 48 (2007), 223–229.
16. [16] Nyalakonda, H., Utay, N.S., A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis 28 (2015), 471–478.
17. [17] Lawitz, E., Mangia, A., Wyles, D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
18. [18] Poordad, F., Lawitz, E., Kowdley, K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368 (2013), 45–53.
19. [19] Jacobson, I.M., Gordon, S.C., Kowdley, K.V., et al., POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 (2013), 1867–1877.
20. [20] Afdhal, N., Zeuzem, S., Kwo, P., et al., ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
21. [21] Afdhal, N., Reddy, K.R., Nelson, D.R., et al., ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
22. [22] Zeuzem, S., Dusheiko, G.M., Salupere, R., et al., VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
23. [23] Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al., ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
24. [24] Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370 (2014), 1983–1992.
25. [25] Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the Aviator study. Presented at: The 48th Annual Meeting of the European Association for the Study of the Liver, April 24–28, 2013, Amsterdam, The Netherlands.
26. [26] Lawitz, E., Sulkowski, M.S., Ghalib, R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
27. [27] Younossi, Z.M., Singer, M.E., Mir, H.M., et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 60 (2014), 530–537.
28. [28] Younossi, Z.M., Stepanova, M., Nader, F., et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 59 (2014), 2161–2169.
29. [29] Younossi, Z.M., Stepanova, M., Henry, L., et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 60 (2014), 741–747.
30. [30] Younossi, Z.M., Stepanova, M., Zeuzem, S., et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 61 (2014), 228–234.
31. [31] Younossi, Z.M., Jiang, Y., Smith, N.J., et al. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology 61 (2015), 1471–1478.
32. [32] Younossi, Z., Henry, L., The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 46:Suppl. 5 (2014), S186–S196.
33. [33] Younossi, Z.M., Stepanova, M., Afdhal, N., et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 63 (2015), 337–345.
34. [34] Wells, G.A., Russell, A.S., Haraoui, B., et al. Validity of quality of life measurement tools—from generic to disease-specific. J Rheumatol Suppl 88 (2011), 2–6.
35. [35] Wiebe, S., Guyatt, G., Weaver, B., et al. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 56 (2003), 52–60.
36. [36] Younossi, Z.M., Boparai, N., McCormick, M., A disease-specific health-related quality of life instrument for chronic hepatitis C: CLDQ-HCV. Hepatology, 32(369A), 2000, 838.
37. [37] Younossi, Z.M., Guyatt, G., Kiwi, M., et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45 (1999), 295–300.
38. [38] Loria, A., Escheik, C., Gerber, L., et al. The Chronic Liver Disease Questionnaire-Hepatitis C (CLDQ-HCV): a sensitive and valid health related quality of life instrument. Hepatology, 56, 2012, 646A.
39. [39] Brazier, J.E., Harper, R., Jones, N.M., et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305 (1992), 160–164.
40. [40] Medline Plus. Hemoglobin levels. Available from: http://www.nlm.nih.gov/medlineplus/ency/article/003645.htm. [Accessed August 6, 2015].
41. [41] Younossi, Z.M., Kiwi, M.L., Boparai, N., et al. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 95 (2000), 497–502.
42. [42] Popovic, D.D.J., Kovacevic, N.V., Kisic Tepavcevic, D.B., et al. Validation of the chronic liver disease questionnaire in Serbian patients. World J Gastroenterol 19 (2013), 4950–4957.
43. [43] Loria, A., Escheik, C., Gerber, N.L., Younossi, Z.M., Quality of life in cirrhosis. Curr Gastroenterol Rep, 15, 2013, 301.
44. [44] Sanyal, A., Younossi, Z.M., Bass, N.M., et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy—a double-blind placebo-controlled study. Aliment Pharmacol Ther 34 (2011), 853–861.
45. [45] Two, R., Verjee-Lorenz, A., Clayson, D., et al. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health 13 (2010), 128–131.
46. [46] Schulz, K.H., Kroencke, S., Ewers, H., et al. The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res 17 (2008), 575–584.
47. [47] Bondini, S., Kallman, J., Dan, A., et al. Health-related quality of life in patients with chronic hepatitis B. Liver Int 27 (2007), 1119–1125.
48. [48] Dan, A.A., Kallman, J.B., Wheeler, A., et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 26 (2007), 815–820.
49. [49] Kallman, J., O'Neil, M.M., Larive, B., et al. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 52 (2007), 2531–2539.
50. [50] Hirano H, Saito M, Yano Y, et al. Chronic liver disease questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients [published online ahead of print July 31, 2015]. Hepatol Res. http://dx.doi.org/10.1111/hepr.12442.
51. [51] Reeve, Bryce B., PROMIS Cooperative Group. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 45 (2007), S22–S31.
52. [52] Younossi ZM, Stepanova M, Pol S, et al. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study [published online ahead of print June 9, 2015]. Liver Int. http://dx.doi.org/10.1111/liv.12886.
53. [53] Younossi, Z.M., Stepanova, M., Marcellin, P., et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61 (2015), 1798–1808.
54. [54] Ong, J.P., Oehler, G., Krüger-Jansen, C., et al. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicenter observational study. Clin Drug Investig 31 (2011), 213–220.